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Dear Editor,
Approximately 2 % of multiple myeloma (MM) patients
present with hemorrhage at diagnosis. However, hemor-
rhage due to abnormalities in the coagulation system is a
rare complication [1, 2]. Although lupus anticoagulant (LA),
which is infrequently reported to be in association with MM,
is commonly a risk factor for arterial or venous thrombosis,
bleeding tendencies in patients with LA are strongly related
to a low prothrombin activity [3–6]. Acquired hypopro-
thrombinemia with LA, also called LA hypoprothrombine-
mia syndrome (LAHPS), is a rare disease which appears
mostly in young females with systemic lupus erythematosus
or in healthy children after viral infection and is usually
associated with the presence of antiprothrombin antibodies
[7]. We herein report the case of an 86-year-old male with
Bence-Jones protein (BJP) κ-type MM who presented with
hypoprothrombinemia and LA associated with antibodies
directed to the phosphatidylserine–prothrombin complex
(or phosphatidylserine-dependent antiprothrombin antibod-
ies, aPS/PT). The patient was admitted with anemia and had
no past history of bleeding disorders or thrombotic events. A
urinalysis showed massive proteinuria (5.3 g/day), which was
determined to be κ-type BJP using immunoelectrophoresis.
Bone marrow aspiration showed proliferation of abnormal
plasma cells. Computerized tomography showed hematomas
in the bilateral gluteus maximus muscle and the supraclavic-
ular area. Initial coagulation tests showed prolonged pro-
thrombin time and activated partial thromboplastin time
(aPTT) (Table 1). Reduced clotting activity of factors II
(FII), VIII (FVIII), and IX (FIX) was noted in a pattern typical
of that observed in previously reported cases of LAHPS [8, 9].
FVIII and FIX inhibitors were not detected. The prolonged
aPTTwith LA-sensitive aPTT reagent (PTT-LA Roche Diag-
nostics, Tokyo, Japan), which could not be corrected by mix-
ing with normal plasma, suggested the presence of LA. The
results were confirmed using the Staclot LA® assay, and the
dilute Russell viper venom time test was used to confirm the
presence of LA with the phospholipid-neutralizing LA test
(Gradipore, Frenchs Forest, Australia). IgG/M anticardiolipin
antibodies and IgG aPS/PT were negative, while strong pos-
itive IgM aPS/PT was detected, which was measured with
ELISA using the phosphatidylserine–prothrombin complex as
antigen immobilized on ELISA plates in the presence of
CaCl2 [10]. Based on these findings, the patient was diag-
nosed as MM with LAHPS associated with aPS/PT and trea-
ted with melphalan and prednisolone (MP) therapy. The FII
levels were observed to normalize after one cycle of MP
therapy and the patient has remained in remission without
any hemorrhage for 10 months.
In our case, aPTT continued to be prolonged with re-
duced levels of FVIII and FIX in spite of normalizing the FII
level after therapy. LA and IgM aPS/PT remained positive,
although these values were improved, suggesting that the
presence of LA might have an influence on coagulation tests
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after treatment. There are very rare reports showing the
presence of aPS/PT in patients with LAHPS [9]. These
reports describe the patients as having bleeding tendencies
with mildly reduced FII levels, similar to that observed in
our patient. However, in previously reported child cases of
LAHPS, severe hemorrhage usually occurs when the FII
levels are very low (under 10∼15 %). It is possible that
other coagulation factors associated with aPS/PT in LAHPS
might be present. A diagnosis of LAHPS should always be
considered in MM patients with bleeding tendencies
associated with LA, and aPS/PT detection should be per-
formed in conjunction with LA tests.
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Table 1 Laboratory findings
MP therapy Normal values
Before After
3 courses 6 courses
PT (%) 26 56 64 70–130
aPTT (s) 65.3 49.0 44.6 25–38
Fibrinogen (mg/dl) 284 200–400
Factor II (%) 49 93 94 74–149
Factor V (%) 129 70–152
Factor VII (%) 69 63–143
Factor VIII (%) 43 33 43 62–145
Factor IX (%) 9 7 9 74–149
Factor X (%) 74 71–128
Factor XIII (%) 100 >70
LA test
PTT-LA (s) 158.7 <48.2
Staclot LA (s) 58.0 58.1 <8.0





IgM >100 20.8 <13.0
IgG 0 0 <2.0
BJP Positive Negative Negative Negative
Plasma cell (%) 54.2 2.0 2.8 <3.5
PT prothrombin time, dRVVT dilute Russel’s viper venom time
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